Adalvo And Gedeon Richter Join Forces On Semaglutide
Deal On Injectable Obesity Treatment Could Pave Way For Broader GLP-1 Partnership
Adalvo and Gedeon Richter have announced a global co-development deal for semaglutide for obesity. Adalvo CEO Anil Okay spoke to Generics Bulletin about the alliance as well as the broader competitive landscape for GLP-1s.
